Post My Press Release

Free Press Release Distribution

Author: chaitanyag (Page 1 of 33)

Plant-based Vaccines Market By Competitive Strategies And Forecast By 2026

Plant serves as an important source to produce cost-effective vaccine derivatives. Plant-based production of vaccine helps to reduce economic burden of infectious disease in emerging economies, owing to its large-scale production and cost-efficiency. Various clinical trials are focused on development of plant-based vaccines in therapeutic indications such as influenza, dengue, flu, and Ebola virus, which can be administered orally. Oral administration of these vaccines reduces the need of needles and syringes, which requires trained immunization staff and also reduces risk of Hospital Acquired Infections (HAIs).

The global plant-based vaccines market size is estimated to be valued at US$ 927.0 million in 2020 and is expected to witness a CAGR of 11.7% over the forecast period (2020–2026).

Existing key players and new entrants in the plant-based vaccines market are focused on extensive clinical trial studies to develop plant-based vaccines for numerous therapeutic applications. 

For instance, Medicago Inc., a clinical-stage biotechnology company, which uses plant-based technologies to develop and produce novel vaccine and antibodies, is cultivating several tobacco plants (Nicotiana tabacum) at Durham’s Research Triangle Park, North America, which will be used in testing and production of the flu vaccine. In March 2018, Medicago conducted phase III clinical trials to develop flu vaccine, which is expected to be launched in the market by 2020-21 influenza season.  Furthermore, researchers require five to six weeks for production of plant-based vaccine, as compared to five to six month period to prepare the vaccine in chicken eggs, which is currently practiced by vaccine manufacturers.

Request For Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/2004

Besides cost-efficiency, plant-based vaccines offer several benefits over conventional egg-based vaccine production, in terms of production time and enhancing immune system of the patient. For instance, Medicago’s Quadrivalent Influenza Vaccine (QIV) is produced using novel Virus-Like Particle (VLP) technology, which offers new approach in vaccine development and production. In VLP technology, vaccine mimics the native structure of viruses, allowing them to easily get penetrated into patient’s immune system. Moreover, the QIV vaccine lacks core genetic material, rendering them to become non-infectious and unable to replicate. This makes plant-based vaccine safe and effective in inducing immune response of patient similar to natural infection without infecting the patient.

Plant-based vaccine production offers better alternative over egg-based and cell-based vaccine production systems, by reducing lead time and increasing reliability and versatility. Furthermore, plant-based vaccine offers greater antigen specificity in disease treatment. Plant-based vaccine production enables manufacturers to create vaccine, which precisely matches the specific strain of influenza virus in patient’s circulation; as in case of flu infection, influenza virus mutates is constantly. For instance, according to Phase III clinical data study published by Medicago, in September 2017, Medicago’s VLP vaccine during the phase II clinical trial stage showed higher antibody and Cell-Mediated Immunity (CMI) responses over comparator conventional vaccine.   

However, several challenges in manufacturing of plant-based vaccines is expected to restrain growth of the market. Plant-based vaccine production is a new technology and involves complex manufacturing and regulatory process. In egg-based production, whole flu viruses are injected into eggs, which then replicate and form the basis for the vaccine. In plant-based vaccine production method, manufacturers use only specific gene, which codes for protein called hemagglutinin, which is responsible for triggering immune system and encodes it into the tobacco plant leaves. In this context, companies need to pursue the U.S. Food and Drug Administration (FDA) approval to state that not only plant-based vaccine is safe and effective, but also the hemagglutinin or other proteins, which can be extracted from the plant leaves are according to the mentioned standard and that the manufacturing process yields a uniform and reliable product.

Although various plant-based vaccines have been developed in various transgenic plants such as insulin in transgenic safflower, taliglucerase alfa in transgenic carrot, avian influenza vaccine in transgenic tobacco, and Ebola vaccine in transgenic tobacco, no plant-derived vaccine is yet approved for human consumption. Moreover, some of the challenges to develop effective vaccines from downstream processing to the implementation of the vaccines include, selection of antigen & plant expression host, uniformity of dosage, and manufacturing of plant vaccines according to Good Manufacturing Practice (GMP) procedures.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2004

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Antithrombin Market Competitive Landscaping and Recent Developments

Antithrombin is a protein present in blood that inhibits blood clotting by inactivating thrombin. Antithrombin is produced by liver and consists of 432 amino acids. There are two major reasons of antithrombin deficiency, which include acquired antithrombin deficiency caused due to other diseases such as nephrotic syndrome, liver failure, severe trauma, and metastatic tumors and inherited antithrombin deficiency caused due to a genetic mutation or abnormality. According to the NCBI (National Center for Biotechnology Information), inherited antithrombin deficiency is a rarely occurring deficiency and only a maximum of 0.2% of the global population has this deficiency. One of the most popular drugs for the treatment of antithrombin deficiency available in the market is ATryn, which was developed by rEVO Biologics and received the U.S. Food and Drug Administration (FDA) approval in 2009. Antithrombin shows synergistic activity with heparin that enhances the antithrombin binding with Thrombin (factor II a) and Factor Xa. Antithrombin III blood test is required to measure the amount of deficiency of antithrombin that is causing the blood to clot more easily than normal.

Antithrombin Market – Market Dynamics

Increasing incidence of coagulation disorders, open heart surgeries, and extracorporeal circulation during hemodialysis is augmenting growth of antithrombin market. According to the Centers for Disease Control and Prevention (CDC), 2015, around 900,000 people is affected from venous thromboembolism every year in the U.S. Furthermore, 5 to 8% of the U.S. population has increased risk of suffering from thrombosis due to one of the several genetic risk factors known as inherited thrombophilia.

Therapeutic drug pipeline or advancements in drug administering technology is also expected to fuel growth of antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT). This therapeutic that can be used for the treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage (Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s product called as ATryn Antithrombin (Recombinant), derived from human blood donors, is used for hereditary antithrombin deficiency and it recently got market approval in the U.S., thereby significantly contributing to the growth of antithrombin market. Therefore, introduction of new types of antithrombin products with different indication over the forecast period is expected to fuel growth of the global antithrombin market. Furthermore, increasing use of antithrombin in combination with heparin is likely to support the growth of antithrombin market. For instance, heparin resistance in cardiac surgery is likely to create opportunities for use of antithrombin products in anticoagulation therapy.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2018

However, increasing regulations on animal testing have impeded a number of healthcare companies from manufacturing new drugs, thereby restraining the market growth.

Antithrombin Market – Regional Analysis

On the basis of region, the global antithrombin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to gain significant traction in the global antithrombin market, followed by Europe, owing to adoption of robust developed technologies and antithrombin therapies, and high awareness and increasing regulatory approval of drugs in these regions.

Moreover, improving healthcare infrastructure in emerging economies such as China and India, and increasing research and development activities are contributing towards the growth of antithrombin market in Asia Pacific region. For instance, in 2016, China Biologic Products, Inc.’s subsidiary, Shandong Taibang Biological Products Co. Ltd., recently obtained approval from the China Food and Drug Administration (CFDA) to begin human clinical trials using its Human Antithrombin III (ATIII) product for the treatment of hereditary and acquired ATIII deficiency which are more prone during surgical or obstetrical procedures, and treatment of thromboembolism.

Antithrombin Market – Competitive Landscape

The antithrombin market is characterized by the presence of few established players. There is stiff competition in the market, as these few players occupy major market share. Key players operating in the global antithrombin market include Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, Scripps Laboratories Inc., GTC Biotherapeutics, Inc.’s, Green Cross Corp., and BDI Pharma.

Click To Reading More On Antithrombin Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Combination Treatment In Aesthetics Market Research, Analysis and Forecasted Healthcare Industry

Combination treatment in aesthetics consists of multiple treatment approaches for improving aesthetic appearance for consumer. It involves both minimally invasive and virtually noninvasive treatment approaches. Combination treatment in aesthetics works on the principle that single modality of treatment cannot offer different advantage each treatment has whereas combination treatment offers best of different treatment. Various treatment approaches under combination aesthetics include, neuromodulators, derma fillers, topical therapies, intense pulsed light photo rejuvenation, laser therapies, radiofrequency based-therapies and ultra-radiofrequency-based therapies. Combination treatment in aesthetics offers couple of advantages such as reduced number of dermatology clinic visits and improved clinical outcome of treatment, as two different cosmetic procedures contributes its own benefits thereby providing synergic effect. Furthermore, multiple modalities of non-invasive therapies are used in combination treatment in aesthetics.

Combination treatment in aesthetics offers unique approach to treat variety of aesthetic problems such as skin resurfacing, hair removal, hyperpigmentation, scar removal, tattoo removal and other treatments. Increasing awareness about various modalities of aesthetic treatment, preference to improve visual / aesthetic appearance, and decreasing device cost is resulting into wide adoption of the combination therapies from both physician end and consumer end.

The global combination treatment in aesthetics market size was valued at US$ 2334 million in 2017, and is expected to witness a CAGR of 9.1% over the forecast period (2018 – 2026).

Increasing incidences of the facial problems (wrinkles, acne, scar, sun damaged skin, stretch marks, and hyperpigmentation) is resulting in to wide utilization of non-invasive as well as minimally invasive cosmetic procedures, which in turn is expected to drive growth of the combination therapies in aesthetics market. Dermatologist are applying the combination of treatment to improve the final outcome with rapid penetration of these procedures. According to the report by International Society of Aesthetic Plastic Surgery titled Global Aesthetic Survey Results published in 2015, around 20 million cosmetic procedures were conducted worldwide, in 2014. This includes 9,645,395 surgical procedures and 10,591,506 non-surgical procedures. According the same source, over 55% of these cosmetic procedures were carried out in 10 countries such as the U.S., Brazil, Japan, Italy, Mexico, Russia, India, Turkey, Germany, and France.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2066

According to Plastic Surgery Statistics Report, 2017, by American Society for Plastic Surgeons, in 2017, 4% increase was observed in patient’s base, which underwent multiple therapies for same cosmetic treatment. Moreover, over 14 million minimally invasive cosmetic procedures were performed that include, botulinum toxin type- A, soft tissue fillers, laser hair removal, laser skin resurfacing, microdermabrasion, and others. Preference for combination treatment is expected to improve with enormous adoption of minimally invasive therapies, which in turn is expected to boost the combination treatment in aesthetics market growth. However, lack of reimbursement for cosmetic procedures by insurance companies is expected to limit the utilization of the procedure, in turn restraining growth of the market. According to the American Society of Plastic Surgeons (ASPS) in 2017, each session of the non-ablative laser treatments cost around US$ 1,031 per session, while ablative treatments cost around US$ 2,330 per session. Furthermore, no standard guidelines are available for implementing combination treatment in aesthetic, which may lead to slower adoption of this approach.

Various manufacturers are launching derma fillers-based, neuromodulators-based and device- based new products thereby helping in high adoption of multiple platforms for aesthetics treatment especially in skin health sector. This in turn is expected to propel growth of the combination treatments in aesthetics market. For instance, in January 2018, Korea-based Lutronic launched a new laser device— Lase MD— for skin rejuvenation. It is 1,927 nm Thulium laser, which is designed to provide customized skin resurfacing to patients of all ages and skin-type, through fractionated treatments with minimal downtime. The laser with device creates micro-channels with minimal disruption to the outermost layer of the skin, stratum cornium, and leaves the tissues untouched for better permeability and fast healing.

In April 2018, Merz GmbH launched its hyaluronic acid-based dermal filler product— Belotero Lips— for lip enhancement and treatment of perioral lines.

Key players operating in the combination treatments in aesthetics market include, Syneron Medical Ltd., Allegern, Inc., Hologic, Inc., Cynosure, Inc., Merz GmbH and KGaA, Bausch Health Companies, Galderma S.A., Cutera Inc., Alma Lasers, Ltd., Lutronic Corporation, Lumenis Ltd., Cutera, Inc., Strata Skin Sciences, Inc., BISON MEDICAL, Solta Medical Inc., Lynton Lasers Ltd. and Sciton, Inc.

Click To Reading More On Combination Treatment In Aesthetics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Adaptive Strollers Market Modest Situation Among the Top Manufacturers

Adaptive stroller is a special mobility equipment that is designed to offer smooth mobility and comfortable seating for patients with neurodegenerative disorders. It offers a lighter and more portable alternative to wheelchair. Adaptive strollers can be equipped with accessories that help with comfortable positioning and posture. For younger children, strollers are an appropriate alternative to a wheelchair and are more easily transported in cars than heavier wheelchairs. Adaptive strollers are available for nearly all sized clients and frame adjustments and seating options vary significantly among different models.

The global adaptive stroller market size was valued at US$ 313.4 million in 2017 and is expected to witness a CAGR of 7.8% over the forecast period (2018 – 2026)

Neurodegenerative disease is an array of conditions, which primarily affects the neurons in the human brain. It is an incurable and devastating conditions that results in progressive degeneration and death of nerve cells, which causes problems with movement or mental functioning. Spinal Muscular Atrophy (SMA) and motor neuron diseases are the most common neurodegenerative diseases in children. SMA affects the motor neurons that control body movement.

According to a report published in the PLOS One journal, 2018, SMA is the leading genetic cause of infant death worldwide, with an incidence of around 1 per 10,000 newborns worldwide. Cerebral palsy is also the most common motor disability in childhood. According to the Centers for Disease Control and Prevention’s (CDC) 2014 report, an average of one in every 323 children in the U.S. suffer from cerebral palsy.

Adaptive Strollers Market Restraints

High product cost and limited features as compared to wheelchair are the major factors expected to confine the adaptive stroller market growth during the forecast period. Adaptive strollers generally use the same manufacturer’s seating options, whereas manual wheelchairs can accommodate a variety of manufacturers’ seating systems and components, depending on the customer need.

Adaptive Strollers Market – Regional Insights

On the basis of region, the global adaptive strollers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America adaptive strollers market is expected to generate major revenue share during the forecast period. This is owing to increasing investment of government in the healthcare sector coupled with a large number of children suffering from mobility disorders. According to the CDC 2014 report, the expenditure on treatment for a child with Autism Spectrum Disorder (ASD) was US$ 17,000, annually and it increased to over US$ 21,000, annually for a child with more severe ASD.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2253

Europe adaptive stroller market size is expected to witness significant growth, owing to higher prevalence of SMA in the region and increasing charity and funding for adaptive stroller by various government and private organizations such as The ACT Foundation, Action For Kids, and Cerebra. According to the NHS 2014 report, approximately 5,500 to 6,000 people in the UK were suffering with some form of SMA.

Neurodegenerative disease is an array of conditions, which primarily affects the neurons in the human brain. It is an incurable and devastating conditions that results in progressive degeneration and death of nerve cells, which causes problems with movement or mental functioning. Spinal Muscular Atrophy (SMA) and motor neuron diseases are the most common neurodegenerative diseases in children. SMA affects the motor neurons that control body movement. According to a report published in the PLOS One journal, 2018, SMA is the leading genetic cause of infant death worldwide, with an incidence of around 1 per 10,000 newborns worldwide. Cerebral palsy is also the most common motor disability in childhood. According to the Centers for Disease Control and Prevention’s (CDC) 2014 report, an average of one in every 323 children in the U.S. suffer from cerebral palsy.

Adaptive Strollers Market Restraints

High product cost and limited features as compared to wheelchair are the major factors expected to confine the adaptive stroller market growth during the forecast period. Adaptive strollers generally use the same manufacturer’s seating options, whereas manual wheelchairs can accommodate a variety of manufacturers’ seating systems and components, depending on the customer need.

Adaptive Strollers Market – Regional Insights

On the basis of region, the global adaptive strollers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America adaptive strollers market is expected to generate major revenue share during the forecast period. This is owing to increasing investment of government in the healthcare sector coupled with a large number of children suffering from mobility disorders. According to the CDC 2014 report, the expenditure on treatment for a child with Autism Spectrum Disorder (ASD) was US$ 17,000, annually and it increased to over US$ 21,000, annually for a child with more severe ASD.

Europe adaptive stroller market size is expected to witness significant growth, owing to higher prevalence of SMA in the region and increasing charity and funding for adaptive stroller by various government and private organizations such as The ACT Foundation, Action For Kids, and Cerebra. According to the NHS 2014 report, approximately 5,500 to 6,000 people in the UK were suffering with some form of SMA.

Increasing prevalence of brain and spinal cord injuries, cerebral palsy, and disorders such as autism spectrum disorder and Spinal Muscular Atrophy (SMA) are the major factors driving the global adaptive stroller marker size. SMA affects motor nerve cells in the spinal cord and affects the person’s ability to eat, walk, or breathe. According to the Cure SMA 2018 data, SMA affects around 1 in every 11,000 infants and around 1 in every 50 U.S. people is a genetic carrier of spinal muscular atrophy. Moreover, according to a report by the Centers for Disease Control and Prevention (CDC), 2014, one in every 59 children in the U.S suffers from Autism Spectrum Disorder (ASD). All these factors are expected to boost demand for adaptive strollers over the forecast period.

However, high price of adaptive strollers is expected to refrain people in emerging and under developed regions from buying expensive adaptive strollers. Therefore, high product cost of these strollers is a major factor restraining growth of the adaptive stroller market.

Click To Reading More On Adaptive Strollers Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Positive Outlook for Bone Sonometer Market in 2019, But Will it Last?

Bone sonometer is also called as bone densitometry equipment in which sound waves on interaction with bone tissue gives information about elastic and structural properties of tissue. Bone faces slow degradation over period of time by microscopic fracture, fatigue damage, loss of bone mass with aging or nutritional deficiency at birth.  By assessing bone health, bone sonometer can predict the risk for osteoporosis and fracture due to this condition. Various peripheral skeletal sites that can be assessed with bone sonometer include calcaneus, phalanges of the hand, and tibia. In addition, it can also assess the structural and biomechanical properties of bones that contribute to bone strength.

Bone sonometer is comparatively safer technique against other densitometry equipment such as dual energy X-ray absorptiometry and peripheral quantitative computed tomography, which causes exposure to ionizing radiation. It is also simple to use and easy to move due to portability features. Moreover, bone sonometer measures bone in two dimensions, providing only an estimation of bone density. It is used to check mineral status in all age groups including children, adults, and geriatric population.

The global bone sonometer market size was valued at US$ 864.3 million in 2017, and is expected to witness a CAGR of 5.32% over the forecast period (2018 – 2026).

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2269

Increasing incidence of fracture due to osteoporosis would be major reason for growth of the bone sonometer market. According to International Osteoporosis Foundation statistics in 2017, over 8.9 million fractures are caused due to osteoporosis, annually. Furthermore, according to same source, around 200 million postmenopausal women suffer from osteoporosis, globally. According to Centers for Disease Control and Prevention (CDC), in 2016, around 25% women aged 65 and above were suffering from osteoporosis of the femur neck or lumbar spine, and needed treatment. Such instances will in turn fuel growth of the bone sonometer market.

However, growth of bone sonometer market may be restrained majorly due to wider adoption of other scanning technique such as dual energy X-ray absorptiometry. These instruments are widely available and it takes short scanning time as against the quantitative ultrasound devices such as bone sonometer. Various new dual energy X-ray absorptiometry products are launched, which may hinder growth of the bone sonometer market. There is logical corollary between innovation in bone sonometer products and growth of the bone sonometer market, especially in developed regions such as North America and Europe that already has one of the highest per capita expenditure and strong healthcare infrastructure.

Most of the key manufacturers of bone sonometer are focusing on providing portable models, which can be easily connected with computers and digital platforms, take less amount of examination time, and easy to carry anywhere. Pegasus Smart is one such bone sonometer by DMS imaging, which takes only about one second to examine bone density at peripheral bones. It can store up to 300 examination images and these images can be transferred to laptop or computer on permanent workstation such as electronic health record or population health management, for easy access. Some devices offer age group specific configuration (neonatal, pediatric, and adults) and multisite density scanning as against traditional bone sonometer that is mostly used at calcaneus and phalanges.

Moreover, according to the analysis by Coherent Market Insights, increasing number of geriatric population worldwide, is expected to propel growth of the bone sonometer market. Geriatric populations are the most affected age group from bone fracture due to lowered bone density level. Early estimation of bone health could significantly save incidence of fractures. According to the World Population Prospects Report, published in 2017, the worldwide population is advancing toward higher age group. In 2017, an estimated 962 million people were aged 60 years or over, which comprised 13% of the population, worldwide. Moreover, the number is expected to reach 1.3 billion by 2025, registering a growth of around three percent, annually.

Key players operating in the global bone sonometer market include Hologic, Inc., GE Healthcare, Echolight, DMS Imaging, Osteocys Co. Ltd., BeamMed Ltd., Medilink, and Furuno Electric Co., Ltd.

Click To Reading More On Bone Sonometer market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Oncology Drugs Market Product Opportunity, Industry Summary, Constraints

The global Oncology Drugs Market size is estimated to be valued at US$ 77.3 billion in 2018 and is expected to witness a CAGR of 12.3% over the forecast period (2018 – 2026).

Cancer is a class of chronic disease that is characterized by uncontrolled growth of cells. The most common cancer types are breast cancer, lung cancer, colorectal cancer, uterine cancer, and thyroid cancer. The three main types of drugs used for cancer, based on their mechanism of action, are cytotoxic drugs, targeted drugs, and hormonal drugs. Oncology drugs market has witnessed tremendous growth in the recent past, owing to increasing drug approvals and emergence of biosimilar products for cancer treatment. Furthermore, increasing healthcare expenditure for cancer has led to growing research and development activities for developing new cancer drugs that are highly effective and with least side-effects.

Key companies in the oncology drugs market are focused on targeting cancer treatment based on personalized medicines. According to Tufts Center for the Study of Drug Development (CSDD), 2015 report, 73% of the cancer medicines in the development have potential to be personalized medicine. Several researches are focused on targeting cancer at molecular level to offer new cancer treatments. According to an article published in The Biopharmaceutical Pipeline, 2013, new molecular entity for cancer treatment holds 80% share in the total pipeline products for cancer treatment. According to same source, the total number of potential first-in-class projects for cancer are 4,358 out of total 5,473 cancer projects.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2332

However, several blockbuster oncology drugs are expected to lose their patent during 2018-2020, which in turn is expected to hamper the market growth during the forecast period. For instance, Roche’s Avastin, which is a humanized monoclonal antibody for the indication of colorectal, lung, breast, glioblastoma, kidney, and ovarian cancer is expected to lose its patent in July 2019 in the U.S. and in January 2022 in Europe. Some of the other drugs that are under patent expiration include, Bristol-Myers Squibb and Eli Lilly and Company’s Erbitux (cetuximab) by 2018; Roche’s Herceptin (trastuzumab) by 2019 and MabThera (Rituximab) by 2018; and Sanofi’s Zaltrap by 2020.

Presence of key market players and increasing drug approvals are attributing to the highest share of North America market in the global oncology drugs market

Regional oncology drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America oncology drugs market holds dominant position in the global oncology drugs market. Advanced medical treatment options available for cancer in economies such as the U.S. and increasing survival rate are key factors driving the market growth. For instance, according to the American Association for Cancer Research’s 2015 report, the number of survivors suffering from cancer increased from 9.8 million in 2001 to 14.5 million in 2014, owing to increasing adoption of better medical facilities. Moreover, increasing R&D activities by local players such as Spark Therapeutics, Inc. and Kite Pharmaceuticals and increasing product approvals by the U.S. FDA are boosting the market growth in North America.

Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to increasing focus of international player on strategies such as mergers and acquisitions. For instance, in February 2018, Merck acquired Viralytics Limited, a Sydney-based immune-oncology drug developer, to strengthen its immune-oncology drug pipeline. Moreover, increasing prevalence of various types of cancer in economies such as India and China is also expected to propel growth of the market. For instance, according to the American Cancer Society, 2015, around 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer deaths.

Click To Reading More On Oncology Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Intraoperative Monitoring Electrodes Market Insights,Status, Government Policies and Outlook

Intraoperative monitoring electrodes offers useful, real-time ECG data during various mapping or monitoring procedures and are used to transfer energy of ionic currents into electrical current in the body. The currents passed into the body are amplified and used for diagnosis of various diseases. Intraoperative monitoring electrodes offers useful, real-time ECG data during various mapping or monitoring procedures. These electrodes are specifically used in neurological surgery to assess function of the somatosensory pathways during surgical procedures in which the spinal cord, brainstem or cerebrum is at risk to get injured and to localize the sensorimotor cortex.

Intraoperative Monitoring Electrodes Market Drivers

Increasing number of cardiology and neurological diseases worldwide is expected to drive growth of the intraoperative monitoring electrodes market. For instance, according to the World Health Organization (WHO) estimates, in 2012, the global geriatric population was pegged at 901 million in 2015, which is expected to increase over 2 billion by 2050. Geriatric population is highly susceptible to various cardiac and neurological diseases, in turn propelling demand for early disease diagnosis, which can be achieved using monitoring electrodes.

Furthermore, increasing preference for minimally invasive treatment procedures, use of nanotechnology for developing miniaturized electrodes, growing investments on research and development, and focus on early diagnosis of diseases are further expected to boost the global intraoperative monitoring electrodes market growth.

Technological advancement in the field of monitoring electrodes have resulted in high demand for intraoperative monitoring electrodes. For instance, in January 2015, researchers at North Carolina State University introduced a new dry sensor to monitor Electrocardiography (ECG) and Electromyography (EMG) all day long with excellent accuracy, even in situations when wet sensors are ineffective.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2362

Intraoperative Monitoring Electrodes Market Regional Analysis

North America is expected to hold a dominant position in the global intraoperative monitoring electrodes market over the forecast period, owing to the high incidence of neurological and cardiovascular disorders, increasing demand for technologically advanced electrodes, and growing adoption of non-invasive diagnostic electrodes in these region.

According to the Alzheimer’s Association estimates in 2017, around 5 million Americans were diagnosed with Alzheimer’s disease and the number is expected to increase over 16 million by 2050. This creates a highly conducive environment for growth of the intraoperative monitoring electrodes market in North America, especially for neurological applications. Furthermore, installation of technologically advanced electrocardiogram (ECG) and electromyogram (EMG) electrode system by end users have contributed towards the deployment and higher sales of the intraoperative electrode devices in North America.

Intraoperative Monitoring Electrodes Market Restraint

Risk of needle-stick injuries associated with use of subdermal needle electrodes during intraoperative monitoring is expected to limit adoption of intraoperative monitoring electrodes over the forecast period. For instance, according to the data published in Journal of Neurosurgical Anesthesiology in January 2014; there is need to employ steps to minimize the needle sticks, which are used during intraoperative neurophysiologic monitoring (IONM).     

Intraoperative Monitoring Electrodes Market Key Players

Key players operating in global intraoperative monitoring electrodes market include DIXI Medical, Ambu A/S, Blackrock Microsystems LLC, Digitimer Ltd., Cognionics, Inc., Rhythmlink International, LLC, Unimed Electrode Supplies, 3M Company, NuVasive, Inc., Computational Diagnostics, Inc., and Natus Medical Incorporated.

Click To Reading More On Intraoperative Monitoring Electrodes Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

CpG Oligodeoxynucleotide Market Competitive Landscaping and Recent Developments

CpG oligodeoxynucleotide (CpG ODN) is a synthetic oligodeoxynucleotide, which contains unmethylated CpG motifs derived from bacterial DNA with immunostimulatory activities. CpG ODN is a short single-stranded synthetic DNA molecule, which contains one of each of cytosine triphosphate deoxynucleotide and guanine triphosphate deoxynucleotide that makes up the C component in the molecule.

The CpG motifs are considered pathogen-associated molecular patterns (PAMPs), as they are present in microbial genomes in abundance, but are rarely present in vertebrate genomes. These CpG PAMPs are recognized by the pattern recognition receptor (PRR) toll-like receptor 9 (TLR9), which is constitutively expressed only in B cells and plasmacytoid dendritic cells (pDCs) in humans and other higher primates. CpG ODNs show great potential for attachment in prophylactic vaccines designed to prevent infection. Various research companies are targeting synthetic CpG ODN due to the type I pro-inflammatory response it produces and its successful use as vaccine adjuvants.

CpG Oligodeoxynucleotide Market – Dynamics

Increasing demand for vaccination across the globe is expected to contribute to significant growth of the CpG oligodeoxynucleotide market over the forecast period. For instance, according to the UNICEF-Vaccination & Immunization Statistics, in 2017, around 123 million children got immunized with lifesaving vaccines across the world. Moreover, according to the Centers for Disease Control and Prevention (CDC), at least 3,153,876,236 doses of vaccines were distributed in the U.S. from 2006 to 2016.

Rising prevalence of new chronic diseases and the demand for reducing the occurrence of childhood diseases such as polio and others are expected to propel growth of the CpG oligodeoxynucleotide market. According to the Centers for Disease Control and Prevention (CDC), around 25.3 per 100,000 children die at the age of 1-4 years due to congenital malformations, deformations, and chromosomal abnormalities, and others.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2367

CpG Oligodeoxynucleotide Market – Regional Insights

On the basis of geography, the global CpG oligodeoxynucleotide market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America held dominant position in the global CpG oligodeoxynucleotide market in 2017. This is owing to high mortality due to various diseases such as pneumonia, diphtheria, pertussis, and others is expected to propel growth of the market in this region. For instance, according to the Centers for Disease Control & Prevention (CDC), in 2016, around 48,632 children died from pneumonia, which was around 15.1 per 100,000 population in the U.S.  

Moreover, Asia pacific is expected to witness significant growth in the CpG oligodeoxynucleotide market, owing to rising focus on R&D along with mass manufacturing of cheap and affordable vaccines in the region. For instance, according to the International Vaccine Institute (IVI), India became the new hub for vaccine research with over 60% of the world’s vaccines manufactured in India in 2016.

CpG Oligodeoxynucleotide Market – Competitive Landscape

Major players operating in the global CpG oligodeoxynucleotide market include Novus Biologicals, InvivoGen, Merck KGaA, Hycult Biotech, Miltenyi Biotec, Sapphire Bioscience, Biomol GmbH, and Cosmobio. Key players are focused on adopting market strategies such as mergers and acquisitions, and new product development, in order to retain dominant position in the market. For instance, in July 2014, Techne Corporation acquired Novus Biologicals, a Colorado-based supplier of outsourced and in-house developed antibodies for life science research, for around US$ 60 million in cash.

Click To Reading More On CpG Oligodeoxynucleotide Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Page 1 of 33

Powered by WordPress & Theme by Anders Norén